Collegium Showcases Real-World Data on Jornay PM for ADHD at Major Psychiatry Conferences

Collegium Pharmaceutical Inc. announced upcoming poster presentations at the American Academy of Child & Adolescent Psychiatry (AACAP) and Neuroscience Education Institute (NEI) conferences, highlighting real-world data from its neuropsychiatry product, Jornay PM (methylphenidate HCl). The studies focus on the real-world use, utilization, and patient response to Jornay PM for the treatment of attention deficit hyperactivity disorder (ADHD) in individuals aged six years and older. One poster, titled “Determining the Optimal Dose of Methylphenidate HCI (JORNAY PM) in Adolescents and Adults in a Real-World Psychiatric Setting,” is scheduled for presentation at AACAP in Chicago on October 22, 2025. Another poster, “JORNAY PM® in Practice: Real-World Evidence Exploration of Utilization and Patient Response,” will be presented at the NEI Fall Congress in Colorado Springs on November 7, 2025. The results from these studies will be presented at the respective conferences. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Collegium Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9549687-en) on October 22, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)